Projects
Pharmacoeconomic Policy Model
Developed cost-effectiveness models to evaluate high-cost drug therapies, influencing payer reimbursement policies in the US healthcare system.
2023 – Present
Epidemiology & Public Health Study
Led a large-scale epidemiological survey analyzing disease prevalence in underserved populations, creating data pipelines for public health interventions.
2015 – 2017
Microbiome & Heart Health
Investigated the link between oral bacteria and heart risks (obesity & hypertension) in adolescents, identifying early predictive markers.
2020-2021
Smokeless Tobacco Epidemiology
Conducted a cross-sectional study on smokeless tobacco consumption among heavy-load drivers, highlighting cancer risks in underserved communities.
2017
OHIP-14 Quality of Life Model
Validated the 'Oral Health Impact Profile' (OHIP-14) for patients with liver and GI disorders, creating a new standard for measuring patient well-being.
2018
Global Systematic Reviews
Conducted comprehensive meta-analyses on clinical datasets to generate high-level evidence for medical guidelines and treatment protocols.
2019-2022
Pharmacoeconomic Policy Model
Developed cost-effectiveness models to evaluate high-cost drug therapies, influencing payer reimbursement policies in the US healthcare system.
2023-Present
Sanofi Market Access
Directed a $15M rare disease portfolio, driving 50% revenue growth for key therapies.
2021-2022
MammoCheck Strategy
Designed U.S. market entry strategy, accelerating speed-to-market by 40% with $50M+ projected revenue.
2023-2024
Gastro-Dental AI Analytics
Leveraged machine learning on national datasets to decode the link between oral health and gastrointestinal diseases.
2019-2021
COVID-19 AI Diagnostics
Achieved >90% predictive accuracy using AI models, reducing diagnostic costs by 60%
2020-2021
Fabry Disease PRO Instrument
Developed a validated patient-reported outcome measure to support global drug launch evidence.
2022-2023
Microbiome & Heart Health
Investigated the link between oral bacteria and heart risks (obesity & hypertension) in adolescents, identifying early predictive markers.
2020-2021
Salivary Biomarker Discovery
Pioneered non-invasive diagnostic models using salivary proteins to detect systemic diseases with high sensitivity.
2018-2020
Epidemiology & Public Health Study
Led a large-scale epidemiological survey analyzing disease prevalence in underserved populations, creating data pipelines for public health interventions.
2015-2017
Smokeless Tobacco Epidemiology
Conducted a cross-sectional study on smokeless tobacco consumption among heavy-load drivers, highlighting cancer risks in underserved communities.
2017
Global Systematic Reviews
Conducted comprehensive meta-analyses on clinical datasets to generate high-level evidence for medical guidelines and treatment protocols.
2019-2022
Questions & Answers
What types of organizations do you partner with?
I work with a diverse range of clients, including top-tier Pharmaceutical Companies, Biotech Startups, Healthcare Systems, and Public Health Policymakers. Whether you need Global Market Access strategy or Clinical Validation, I tailor my approach to your specific scale and goals.
How do you integrate AI into clinical research?
My methodology combines Real-World Evidence (RWE) with advanced Machine Learning models. This allows us to predict patient outcomes, optimize clinical trial designs, and reduce speed-to-market, ensuring that every strategy is backed by rigorous data analytics.
Can you support regulatory submissions (FDA/EMA)?
Yes. A key part of my work involves generating high-quality Health Economics & Outcomes Research (HEOR) data. I help structure scientific evidence and dossiers that align with regulatory requirements for bodies like the FDA and EMA to support successful product launches.
What is your engagement model? (Project vs. Retainer)
I offer flexible engagement models depending on your needs. This ranges from Project-Based Consulting for specific deliverables (e.g., a Market Entry Strategy) to Long-Term Advisory Retainers for ongoing scientific leadership and R&D support.
How do you handle data privacy and compliance?
Data integrity is paramount. I adhere to strict global standards, including HIPAA and GDPR, ensuring that all patient data and proprietary client information is handled with the highest level of security and confidentiality throughout the project lifecycle.